PHOENIX, AZ--(NewMediaWire - Nov 7, 2017) - Corix Bioscience
Inc. (OTCQB: CXBS) has purchased 100% of Pharmaceutical
Development Corp., allowing Corix to commence selling its
proprietary cannabis products internationally.
Michael Ogburn, Corix Bioscience CEO, stated, "This is a
defining moment for our company. It allows us to grow and
manufacture cannabis in Lesotho and distribute our products to
dozens of other countries. It will allow us to accelerate our
growth very quickly. This deal will help us grow into the
powerhouse company we anticipate to be in 2018."
Pharmaceutical Development's manufacturing facility is in
Lesotho, a landlocked country located in South Africa. It received
the first cannabis license in all of South Africa. They have an
export treaty that allows them to export cannabis and CBD oil to
approximately 30 plus different countries in the EU, Canada,
Australia, Mexico, Brazil and New Zealand.
About Corix Bioscience Inc.
Corix Bioscience Inc. ("Corix") is a Wyoming corporation and is
fully reporting with the SEC and is listed as OTCQB: CXBS. Corix is
the developer of proprietary cannabis and industrial hemp strains
using tissue cell cultures to propagate living plants, with plans
to patent the strains to be used in the pharmaceutical medical
industries.
Our methods allow us to create and breed new and existing plant
strains from tissue cells free of any pathogens or disease. We grow
these plants to maturity and extract the oils which are the
"medicine" part of the plant. Our sales are focused towards the
medical industry and we are developing brand named products to be
released in early 2018.
Corix has offices in Irvine, CA., Phoenix, Arizona, a laboratory
and processing facility in Carson City, Nevada, a research and
development grow operation in Adelanto, CA., and fields for growing
the plants in Genoa, Nevada. We are currently looking at expanding
our footprint into Washington, Oregon and Colorado. The Company's
mission is to create clean and consistent products in medical grade
facilities. Consistency being the key which will ultimately yield a
safer and superior product, better for people and the environment.
For more information, please visit Corix's website
at www.corixbioscience.com
Forward Looking Statement
This press release, and those statements regarding IXB and the
Company, contain forward-looking statements that relate to
expectations, beliefs, projections, future plans and strategies,
anticipated events and similar expressions. Forward-looking
statements may be identified by use of words such as "may," "will,"
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," or "potential" or similar words or phrases which are
predictions of or indicate future events or trends. Statements such
as those concerning potential acquisition activity, investment
objectives, strategies, opportunities, other plans and objectives
for future operations or economic performance are based on the
Company's current expectations, plans, estimates, assumptions and
beliefs that involve numerous risks and uncertainties. You are
cautioned not to place undue reliance on any forward-looking
statements and the Company disclaims any obligation to publicly
update or revise any forward-looking statement to reflect changes
in underlying assumptions or factors, new information, future
events or other changes. Please refer to Company's filings with the
Securities and Exchange Commission for further
information.
